Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common antioxidant help COVID-19 patients breathe easier?

NCT ID NCT07374991

Disease control Sponsor: University of Gaziantep Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether N-Acetylcysteine (NAC), an antioxidant, could help people with severe COVID-19 lung failure in the ICU. 59 adults received either NAC or a placebo alongside standard care. Researchers measured changes in inflammation markers and tracked survival and length of ICU stay.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
N-Acetylcysteine (NAC)
What this could lead to
If it works, NAC could become a cheap, widely available add-on treatment to reduce inflammation and improve survival in severe COVID-19 lung injury.
What could go wrong
This is a small, completed trial with only 59 participants. Results may not apply to all patients, and NAC's benefits are uncertain until larger studies confirm them.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

59 people

The number who actually took part.

Started

Nov 2020

Finished

Oct 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria:Age ≥18 years PCR-confirmed SARS-CoV-2 infection Diagnosis of acute respiratory distress syndrome (ARDS) according to the Berlin criteria Admission to the intensive care unit Written informed consent obtained from the patient or legal representative - Exclusion Criteria:Expected mortality within 48 hours of ICU admission Prior chronic oxygen therapy Previous COVID-19 treatment initiated at another center Pregnancy or breastfeeding Use of antioxidant or anti-inflammatory drugs within 30 days prior to enrollment Known hypersensitivity to N-acetylcysteine Use of medications affecting glutathione metabolism \-

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19-associated acute respiratory distress syndrome (ARDS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19-associated acute respiratory distress syndrome (ARDS)

Contacts and locations

Locations

  • Gaziantep üniversity

    Gaziantep, 27, Turkey (Türkiye)